Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.220
+0.030 (2.52%)
At close: Sep 18, 2026, 4:00 PM EDT
1.250
+0.030 (2.46%)
After-hours: Sep 18, 2026, 8:00 PM EDT
Actinium Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
The conference highlighted a robust pipeline in targeted radiotherapy, with lead programs advancing in AML, solid tumors, and cell/gene therapy. Promising clinical data, large market opportunities, and a strong financial position support continued growth and partnership opportunities.
-
Multiple revitalized clinical programs, including Actimab-A and Iomab-ACT, are advancing with new trials in AML and solid tumors, supported by strong financials and enhanced R&D. A novel prostate cancer therapy, ATNM-400, showed promising preclinical results.